NCT04650269

Implementation of Onsite, Rapid ART Initiation Among People Who Inject Drugs Living With HIV at Syringe Services Program

Implementation of Onsite, Rapid Antiretroviral Therapy (ART) Initiation Among People Who Inject Drugs Living With HIV at Syringe Services Program

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 27 (actual)
• Sponsor: University of Miami · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to see if providing HIV medicine right away at the IDEA Syringe Services Program will help the participant start and remain in HIV care, including having no detectable HIV in the participant's blood.

Conditions

• Harm Reduction
• HIV Infections
• Drug Use

Interventions

Type	Name	Description
DRUG	Biktarvy 50Mg-200Mg-25Mg Tablet	Daily Biktarvy (50/200/25mg) combination ART by mouth for 6 months
OTHER	HIV care	HIV primary care (including Biktarvy delivery) will be conducted outside of a clinical setting by a community-based harm reduction program for 6 months.

Timeline

• Start date: 2021-03-04
• Primary completion: 2023-12-31
• Completion: 2023-12-31
• First posted: 2020-12-02
• Last updated: 2025-01-08
• Results posted: 2025-01-08

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study